US health chiefs issued a warning about RSV jabs, which were only launched in Britain last year.In the UK, the condition is already noted as a potential complication in patient information.
A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...
Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).
The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback